A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Sunitinib Malate (Sutent)

Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 1 week washout period. The dosage may change during the cycle due to possible drug toxicities. The nephrectomy will then take place following a one-week washout period.

Trial Locations (1)

M5G 2M9

University Health Network, Princess Margaret Hospital, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University Health Network, Toronto

OTHER

NCT00480935 - A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter